Shockwave Medical (SWAV) PT Raised to $149 at Canaccord Genuity

March 31, 2021 7:32 AM EDT
Get Alerts SWAV Hot Sheet
Price: $133.45 -2.6%

Rating Summary:
    2 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 19 | Down: 17 | New: 47
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Canaccord Genuity analyst William Plovanic raised the price target on Shockwave Medical (NASDAQ: SWAV) to $149.00 (from $147.00) while maintaining a Buy rating.

The analyst commented, " Shockwave Medical announced preliminary Q1/21 revenue as well as metrics related to the recent commercial launch of its C2 coronary product this morning, prior to an investor meeting. The company expects Q1/21 revenue to be in the range of$31.0-32.0M (a Y/Y increase of 104%-111%). This compares to our estimate of $23.8Mand consensus estimate of $24.9M. Shockwave also released metrics related to the C2launch that were very encouraging given the product has been commercially available for only ~6 weeks. This included over 120 accounts who have purchased the product already, with an average of 6 units per account. Further, ~50% of U.S. accounts that have initiated launch have completed the launch training activities and are able to use IVL independently – showing that SWAV’s strategy is working. We have updated our estimates to reflect the Q1/21 revenue preannouncement as well as the encouraging adoption trends of C2. We maintain our BUY rating and raise our PT to $149 from $147."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Canaccord Genuity